The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

Bibliographic Details
Main Authors: Holt, S V, Logié, A, Odedra, R, Heier, A, Heaton, S P, Alferez, D, Davies, B R, Wilkinson, R W, Smith, P D
Format: Online
Language:English
Published: Nature Publishing Group 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305954/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305954/

Similar Items